Lilly rides Mounjaro, Zepbound to better
Time:2024-05-21 18:49:20 Source:travelViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:Kristin Cavallari, 37, ignores critics of her age
Next:Britain's new bonkers EV: Callum Skye is an £80k electric buggy built in Warwickshire
You may also like
- Nuggets blow 20
- Airbus to set up innovation center in China
- 4th CICPE scheduled from April 13
- China launches new mobile telecommunication satellite
- Not so Cool Britannia! Noel Gallagher gives damning verdict on Keir Starmer
- China, Zambia to Boost Cooperation as Ties Elevated
- China's current account surplus remains in reasonable range
- 'Global status far off for China's carmakers'
- Analysis: Larson enters conversation with Verstappen as best drivers in the world